Article ; Online: COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients.
2022 Volume 54, Issue 1, Page(s) 2856–2860
Abstract: Background: The COVID-19 pandemic caused by SARS-CoV-2 continues to have a serious impact on public health worldwide. Most patients develop mild to moderate symptoms and recover without requiring special treatment, but up to 15% develop severe (dyspnea, ...
| Abstract | Background: The COVID-19 pandemic caused by SARS-CoV-2 continues to have a serious impact on public health worldwide. Most patients develop mild to moderate symptoms and recover without requiring special treatment, but up to 15% develop severe (dyspnea, hypoxia, lung involvement) or critical symptoms (respiratory failure, septic shock, thromboembolism, multiorgan dysfunction). Although vaccination is having a substantial impact on case numbers, hospitalizations and deaths, there remains a need for new effective treatments against COVID-19. Methods: This short review aims at reporting on current therapeutics against SARS-CoV-2 focussing on new drugs authorized in the European Union, describing the treatment strategies and the clinical recommendations for the management of hospitalized and non-hospitalized COVID-19 patients based on the available guidelines for clinical practice. Results: New effective drugs, like antiviral medications and monoclonal antibodies, have been developed as therapy against severe and life-threatening disease courses. Specifically, the European Medicines Agency has authorized two antiviral medicines (nirmatrelvir/ritonavir, remdesivir), supporting also early use of molnupiravir before marketing authorization, and four monoclonal antibodies (regdanvimab, casirivimab/imdevimab, sotrovimab, tixagevimab/cilgavimab). In addition, three drugs (anakinra, tocilizumab, baricitinib) previously authorized for the treatment of rheumatoid arthritis are also available to treat COVID-19. Conclusions: Recommendations and guidelines for clinical practice should be regularly updated as further evidence becomes available in favour or against specific interventions, to inform all stakeholders involved in the health care of COVID-19 patients both in the community and in the hospital setting, aiming at improving the quality of care and therefore the patient outcome.KEY MESSAGESCOVID-19 has been recognized as a multisystem disorder affecting many body systems; this wide spectrum of clinical patterns made difficult an appropriate choice of treatments able to counteract severe symptoms of the disease and alleviate the burden on the healthcare system.New effective drugs, like antiviral medications and monoclonal antibodies, have been developed and approved by the European Medicines Agency as therapy against severe and life-threatening disease courses.Recommendations and guidelines should be regularly updated as further evidence becomes available in favour or against specific interventions aiming at improving the quality of care and therefore the patient outcome. |
|---|---|
| MeSH term(s) | Humans ; COVID-19/drug therapy ; SARS-CoV-2 ; Pandemics ; Ritonavir ; Interleukin 1 Receptor Antagonist Protein ; European Union ; Antibodies, Monoclonal/therapeutic use ; Antiviral Agents/therapeutic use ; Hospitalization |
| Chemical Substances | imdevimab (2Z3DQD2JHM) ; casirivimab (J0FI6WE1QN) ; sotrovimab (1MTK0BPN8V) ; tixagevimab ; regdanvimab (I0BGE6P6I6) ; cilgavimab (1KUR4BN70F) ; Ritonavir (O3J8G9O825) ; Interleukin 1 Receptor Antagonist Protein ; Antibodies, Monoclonal ; Antiviral Agents |
| Language | English |
| Publishing date | 2022-10-19 |
| Publishing country | England |
| Document type | Journal Article ; Review |
| ZDB-ID | 1004226-x |
| ISSN | 1365-2060 ; 1651-2219 ; 0785-3890 ; 1743-1387 |
| ISSN (online) | 1365-2060 ; 1651-2219 |
| ISSN | 0785-3890 ; 1743-1387 |
| DOI | 10.1080/07853890.2022.2133162 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 680: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.